Immunovant (IMVT) Current Assets (2018 - 2026)
Immunovant's (IMVT) quarterly Current Assets came in at $948.8 million in Q1 2026, up 23.6% YoY from $767.7 million in Q1 2025, and down 9.02% on a QoQ basis from $1.0 billion in Q4 2025.
Immunovant (IMVT) Current Assets (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Current Assets data on file, last reported at $948.8 million in Q1 2026.
- Quarterly Current Assets rose 23.6% year-over-year to $948.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $948.8 million (up 23.6% YoY) and the FY2026 annual result came in at $948.8 million, up 23.6% from the prior year.
- Current Assets eased to $948.8 million in Q1 2026, from $1.0 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.0 billion in Q4 2025 to a low of $291.2 million in Q3 2023.
- A 5-year average of $574.4 million and a median of $512.9 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets plunged 41.96% — and 2025, when it jumped 152.81%.
- Tracing IMVT's Current Assets over 5 years: stood at $454.4 million in 2022, then surged by 56.41% to $710.8 million in 2023, then sank by 41.96% to $412.5 million in 2024, then jumped by 152.81% to $1.0 billion in 2025, then dropped by 9.02% to $948.8 million in 2026.
- The last three Current Assets figures came in at $948.8 million (Q1 2026), $1.0 billion (Q4 2025), and $573.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 851.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 851.18 Mn |
| Mar 31, 2026 | 948.82 Mn |
| Dec 31, 2025 | 1.04 Bn |
| Sep 30, 2025 | 573.55 Mn |
| Jun 30, 2025 | 651.76 Mn |
| Mar 31, 2025 | 767.66 Mn |
| Dec 31, 2024 | 412.54 Mn |
| Sep 30, 2024 | 507.37 Mn |
| Jun 30, 2024 | 589.05 Mn |
| Mar 31, 2024 | 665.77 Mn |
| Dec 31, 2023 | 710.78 Mn |
| Sep 30, 2023 | 291.18 Mn |
| Jun 30, 2023 | 350.02 Mn |
| Mar 31, 2023 | 404.33 Mn |
| Dec 31, 2022 | 454.42 Mn |
| Sep 30, 2022 | 426.09 Mn |
| Jun 30, 2022 | 456.30 Mn |
| Mar 31, 2022 | 512.93 Mn |
| Dec 31, 2021 | 540.48 Mn |
| Sep 30, 2021 | 563.79 Mn |